These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9794552)

  • 1. Effects of FK506 on experimental membranous glomerulonephritis induced by cationized bovine serum albumin in rats.
    Kobayashi M; Muro K; Yoh K; Kondoh M; Iwabuchi S; Hirayama K; Ishizu T; Kikuchi S; Yamaguchi N; Koyama A
    Nephrol Dial Transplant; 1998 Oct; 13(10):2501-8. PubMed ID: 9794552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration.
    Iwamoto H; Yoshida H; Yoshida O; Fukushima A; Ueno H
    Graefes Arch Clin Exp Ophthalmol; 1999 May; 237(5):407-14. PubMed ID: 10333108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis.
    Matsukawa W; Hara S; Yoshida F; Suzuki N; Fukatsu A; Yuzawa Y; Sakamoto N; Matsuo S
    J Lab Clin Med; 1992 Feb; 119(2):116-23. PubMed ID: 1371298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats.
    Hayashi K; Nagamatsu T; Ito M; Suzuki Y
    Jpn J Pharmacol; 1996 Jan; 70(1):43-54. PubMed ID: 8822088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3.
    Ikezumi Y; Kanno K; Koike H; Tomita M; Uchiyama M; Shimizu F; Kawachi H
    Kidney Int; 2002 Apr; 61(4):1339-50. PubMed ID: 11918741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesangial overload in experimental membranous nephropathy.
    Soares VA; Fan CD; Ward H
    Braz J Med Biol Res; 1992; 25(5):477-86. PubMed ID: 1342223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the immunosuppressive agent, ciclosporin, on experimental immune complex glomerulonephritis in rats.
    Fujita M; Iida H; Asaka M; Izumino K; Takata M; Sasayama S
    Nephron; 1991; 57(2):201-5. PubMed ID: 1826940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK506 in the treatment of children with nephrotic syndrome of different pathological types.
    Xia Z; Liu G; Gao Y; Fan Z; Fu Y; Zhang LF; Ren X; Gao C
    Clin Nephrol; 2006 Aug; 66(2):85-8. PubMed ID: 16939063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine serum albumin (BSA) nephritis in rats. I. Experimental model.
    Yamamoto T; Kihara I; Morita T; Oite T
    Acta Pathol Jpn; 1978 Nov; 28(6):859-66. PubMed ID: 367054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles.
    Gao S; Sun J; Fu D; Zhao H; Lan M; Gao F
    Int J Pharm; 2012 May; 427(2):410-6. PubMed ID: 22326299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rat bovine serum albumin (BSA) nephritis. VI. The influence of chemically altered antigen.
    Yamamoto T; Miyazaki S; Kawasaki K; Yaoita E; Kihara I
    Clin Exp Immunol; 1986 Jul; 65(1):51-6. PubMed ID: 3539427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental immune complex glomerulonephritis and the nephrotic syndrome in cats immunised with cationised bovine serum albumin.
    Nash AS; Mohammed NA; Wright NG
    Res Vet Sci; 1990 Nov; 49(3):370-2. PubMed ID: 2148430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
    Liang Q; Li H; Xie X; Qu F; Li X; Chen J
    Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis.
    Hara S; Fukatsu A; Suzuki N; Sakamoto N; Matsuo S
    Clin Immunol Immunopathol; 1990 Dec; 57(3):351-62. PubMed ID: 1700936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FK506 therapy of experimental autoimmune myocarditis after onset of the disease.
    Kodama M; Hanawa H; Zhang S; Saeki M; Koyama S; Hosono H; Miyakita Y; Katoh K; Inomata T; Izumi T
    Am Heart J; 1993 Dec; 126(6):1385-92. PubMed ID: 7504393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establish and identification of mouse model of membranous nephropathy].
    Wang H; Wang J; Li J; Li L; Yuan Y; Wang C; Ye J; Li Q
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Feb; 29(2):197-9. PubMed ID: 23388342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoelectron microscopy of cationized bovine serum albumin-induced glomerulonephritis in the rabbit.
    al-Nawab MD; Bass PS; Das AK; Davies DR
    J Pathol; 1992 May; 167(1):33-40. PubMed ID: 1625056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective Effects Of Isoliquiritin Against Cationic Bovine Serum Albumin-Induced Membranous Glomerulonephritis In Experimental Rat Model Through Its Anti-Oxidative And Anti-Inflammatory Properties.
    Liu Y; Xu X; Xu R; Zhang S
    Drug Des Devel Ther; 2019; 13():3735-3751. PubMed ID: 31802848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cationization of bovine serum albumin alters its conformation as well as its charge.
    Bass PS; Drake AF; Wang Y; Thomas JH; Davies DR
    Lab Invest; 1990 Feb; 62(2):185-8. PubMed ID: 2304331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.